Iodinated Tropane Radiopharmaceutical Formulation for Stable DAT Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for Parkinson's Disease are inadequate for early detection due to high misdiagnosis rates and lack of noninvasive, effective tools to measure dopamine transporter depletion in the brain, which is a key indicator of the disease.
Innovation Solution
A radiopharmaceutical formulation comprising an aqueous solution of [123I]-2β-carbomethoxy-3β-(4-fluorophenyl)-N-(3-iodo-E-allyl) nortropane with a high radioactive concentration, specifically designed to maintain activity for an extended period, ensuring sufficient radiochemical purity and stability for use in imaging dopamine transporters in the brain.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If a radiopharmaceutical formulation is designed to maintain high radioactive concentration for extended periods, then the duration of action is improved, but the stability of the radioactive isotope deteriorates due to natural decay
Solution Approach 1:
The patent selects iodine-123 with a specific half-life of 13.2 hours, optimizing the radioactive parameter to balance duration of action with stability. The formulation maintains high radioactive concentration (at least 18 mCi/ml) by controlling the decay parameter through isotope selection and timing of administration, resolving the contradiction between extended duration and isotope stability.
2Measurement precision
If the radioactive concentration is increased to improve detection sensitivity, then the measurement precision is improved, but the harmful factors increase due to higher radiation exposure
Solution Approach 1:
The patent optimizes the radioactive concentration parameter to at least 18 mCi/ml, which provides sufficient detection sensitivity for measuring dopamine transporter depletion. This parameter level achieves the necessary measurement precision while minimizing harmful radiation exposure, as it is the lowest concentration that still enables accurate early detection of Parkinson's Disease.
3Ease of operation
If a noninvasive imaging method is used to detect dopamine transporter depletion, then the ease of operation is improved, but the measurement precision deteriorates due to limitations of noninvasive detection
Solution Approach 1:
The patent uses a radiopharmaceutical copy of the dopamine transporter ligand that can be detected externally via SPECT imaging. The [123I] nisoxetine molecule binds to DAT in the brain, and its radioactive emissions create an external detectable signal that accurately reflects the internal biological state, enabling noninvasive measurement with high precision through the copying of the molecular interaction pattern.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation enables accurate and early detection of Parkinson's Disease by maintaining high radioactive concentration and stability, allowing for effective imaging of dopamine transporter depletion, thereby aiding in diagnosis and monitoring of the disease progression.
Implementation Method 1
a high level of radioactivity is also pertinent. In this regard, iodine isotopes may be useful if they can be produced in sufficiently high concentrations such that they will still be emitting at suitable levels for a useful period of time.
Implementation Method 2
An effective imaging agent for the disorders described above will exhibit a specific binding affinity and selectivity for the transporter being targeted.
Data Source
AI summary
A diagnostic formulation is provided comprising a tropane having a radioactive concentration of at least 1.6 mCi/mL at least about 51 hours post creation. The diagnostic formulation optionally comprises a radiolabeled dopamine transporter (DAT) ligand useful in the diagnosis of Parkinson's disease (PD). One example of a radiolabeled dopamine transporter (DAT) ligand is [123-Iodine]-2ß-carbomethoxy-3-ß-(4-flurophenyl)-N-(3-iodo-E-allyl) nortropane.